Analysis Of Income And Expense [Abstract]

ROQUEFORT THERAPEUTICS PLC - Filing #5968009

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Interest income	—	– GBP	—	—	—	—	—	—	1,469 GBP	—	—	—	—	—
Revenue	—	– GBP	—	—	—	—	—	—	200,000 GBP	—	—	—	—	—
Material income and expense [abstract]
Research and development expense	—	152,915 GBP	—	—	—	—	—	—	620,159 GBP	—	—	—	—	—
Interest expense	—	44,857 GBP	—	—	—	—	—	—	58 GBP	—	—	—	—	—
Expenses by nature [abstract]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation expense	—	5,404 GBP	—	—	—	—	—	—	3,890 GBP	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	– GBP	914,552 GBP	– GBP	– GBP	– GBP	57,251 GBP	971,803 GBP	– GBP	1,717,495 GBP	– GBP	– GBP	1,744,540 GBP	– GBP	27,045 GBP